Reduced risk for chronic kidney disease after recovery from metabolic syndrome: A nationwide populationbased study
- Author:
Sehoon PARK
1
;
Soojin LEE
;
Yaerim KIM
;
Yeonhee LEE
;
Min Woo KANG
;
Kyungdo HAN
;
Hajeong LEE
;
Jung Pyo LEE
;
Kwon Wook JOO
;
Chun Soo LIM
;
Yon Su KIM
;
Dong Ki KIM
Author Information
- Publication Type:Original Article
- From:Kidney Research and Clinical Practice 2020;39(2):180-191
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Metabolic syndrome (MetS) is linked to various chronic comorbidities, including chronic kidney disease (CKD). However, few large studies have addressed whether recovery from MetS is associated with reduction in the risks of such comorbidities.
Methods:This nationwide population-based study in Korea screened 10,664,268 people who received national health screening ≥ 3 times between 2012 and 2016. Those with a history of major cardiovascular events or preexisting CKD were excluded. We classified study groups into four, according to the course of MetS state, as defined by the harmonizing criteria. The main study outcome was incidental CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2 which was persistent until the last health exams). The study outcomes were investigated using multivariable logistic regression analysis, which was adjusted for clinical variables and the previous severity of MetS.
Results:Four study groups included 6,315,301 subjects: 4,537,869 people without MetS, 1,034,605 with chronic MetS, 438,287 who developed MetS, and 304,540 who recovered from preexisting MetS. Those who developed MetS demonstrated higher risk of CKD (adjusted odds ratio [OR], 1.26 [1.23-1.29]) than did those who did not develop MetS. In contrast, MetSrecovery was associated with decreased risk of CKD (adjusted OR, 0.84 [0.82-0.86]) than that in people with chronic MetS. Among the MetS components, change in hypertension was associated with the largest difference in CKD risk.
Conclusion:Reducing or preventing MetS may reduce the burden of CKD on a population-scale. Clinicians should consider the clinical importance of altering MetS status for risk of CKD.
